This trial is evaluating whether Stereotactic Body Radiation Therapy (SBRT) will improve 1 primary outcome and 5 secondary outcomes in patients with Bone Diseases. Measurement will happen over the course of 3 months.
This trial requires 150 total participants across 2 different treatment groups
This trial involves 2 different treatments. Stereotactic Body Radiation Therapy (SBRT) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
These data suggest that patients who are medically stabilized and who are still eligible for clinical trials should be considered to participate in clinical trials.
If a patient would choose to have SBRT, then that is the best care available currently. No significant difference in outcome was observed between patients receiving SBRT and those receiving a placebo.
Surgical techniques, and, in particular, the use of the Cyberknife SBRT system, are continually adapting; these technologies have the potential for further improvement and refinement, and are already being applied in clinical practice in several countries. Some issues remain to be resolved.
Bone diseases can be caused by multiple factors, including mechanical disruption due to osteoclastic or osteoblastic activity, as in case of osteoporosis and [bone cancer](https://www.withpower.com/clinical-trials/bone-cancer), respectively. In addition, bone diseases can be caused by a generalized hypomineralized metabolism induced by factors affecting phosphate metabolism, such as cancer-related factors or malabsorption. The term "skeletal disease" is often used as a synonym for bone disease which is incorrect; it is not necessarily the case that bone diseases are diseases of the skeleton. A diagnosis of a bone disease should consider the cause of the disease and the specific treatment.
Common treatments for bone diseases such as bone metastases and bone cancer include medical, surgical, and/or radiation therapy. These treatments can be used alone or together. Bone metastases often have an extremely poor prognosis, and treatments aim to minimize the pain to allow for quality of life and prolong survival. However, these same treatments have adverse side effects and can worsen the condition of the patient. Therefore, patient choices are key for treatment selection. More research is recommended to improve the current treatments for bone diseases.
As osteoporosis and osteopenia affect more than 1 in 2 women and 1 in 5 men, bone diseases are recognized as an important public health issue. This article describes the clinical features of and diagnostic test results for osteoporosis.
Bones may exhibit pain and swelling, which may occur at sites such as shoulder and knee, or pain along the spine, or pain in one hip or leg. Fractures of certain bones in children may be not be as notificable, as children may not have pain, swelling or mobility issues, and it may take a long time for an X ray to be taken. Children also may have other conditions which may interfere with their ability to take X-rays.\n\nPediatric Emergency Medicine\n\nThe purpose of this article is to list symptoms of a wide range of illnesses and conditions in children. None of the symptoms should be considered specific to any single medical condition.
Findings from a recent study in this study support the concept that some osteoporotic bone diseases can be effectively cured; these include osteopenia, osteoporosis, and osteopetrosis of the femur, spine, and other sites.
The cumulative incidence of osteoporosis, osteopenia and chronic spine pain are high at any given age. In particular, the rate is increased twofold or more in women between the ages of 50 and 64 who did not have osteoporosis as children. Furthermore, if we had assumed that osteoporosis affects every first degree relative between 20 and 49 years, then an assumption of 20% to 24% of this cumulative incidence is justified. These data offer a new basis for population-based prevention programmes.
As of early 2016, there was no evidence of a difference in effectiveness between SBRT and conventional treatments for spine metastases without severe neurological deficits. Because the randomized controlled trials reported in this review used different patient groups, different criteria for spinal cord dysfunction, a different imaging definition of neurological deficit and a different review period, this evidence is inconclusive with regard to the effectiveness of SBRT. Additional high-quality studies are needed.
The majority of patients surveyed reported osteoporosis (54%) or osteopenia (30%) as their primary cause of bone diseases. Other causes, such as other endocrine disorders, nutritional deficiencies, hematologic disorders, hypothyroidism, hyperparathyroidism, hyperparathyroidism due to vitamin D deficiencies, rheumatic disease, and osteitis pubioptica, were described less frequently.
The last few years of new findings are very exciting, and many diseases such as [Tuberculosis] are being treated and cured for the first time. In the future, we must only focus on the diseases, medicines, and treatments. In many autoimmune disease treatments, it seems as if there are a lot of discoveries being made. We have to continue to get a grip on our minds and keep the discoveries coming.